New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
11:28 EDTQEP, ATLS, TMO, NAO, SVU, GLPI, C, KKR, ACT, SDLeon Cooperman gives 12 stock picks at CNBC conference
Leon Cooperman of Omega Advisors gave 12 stock picks for 2014 at CNBC's Delivering Alpha conference. The recommendations are: Actavis (ACT), Citigroup (C), SandRidge Energy (SD), KKR (KKR), Thermo Fisher (TMO), Atlas Energy (ATLS), Gaming and Leisure Properties (GLPI), Nordic American Offshore (NAO), QEP Resources (QEP), SuperValu (SVU), Louis XIII Holdings and Monitise.
News For ACT;C;SD;KKR;ATLS;GLPI;NAO;QEP;SVU;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 9, 2014
10:13 EDTCCitigroup CEO sees $2.7B charges in Q4 to address legal reserve charges
CEO Michael Corbat said that after taking the charges in Q4, the company will be "marginally profitable." Comments taken from Goldman Sachs Financial Services conference.
10:10 EDTCCitigroup to take $3.5B in additional charges in Q4, CNBC reports
Subscribe for More Information
09:38 EDTCActive equity options trading
Subscribe for More Information
09:31 EDTACTZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
08:24 EDTCCitigroup to sell Japanese consumer unit to Sumitomo Mitsui, Bloomberg says
Subscribe for More Information
06:23 EDTSVUSupervalu downgraded after share outperformance at Oppenheimer
Subscribe for More Information
06:14 EDTACTAllergan price target raised to $245 from $210 at Citigroup
Subscribe for More Information
05:59 EDTCCitigroup appointed successor depositary bank for Deutsche Post ADR program
Citi (C), acting through Citibank N.A., has been appointed by Deutsche Post AG (DPSGY) as successor depositary bank for its Level 1 American Depositary Receipt, or ADR, program. Deutsche Post DHL’s ADR program trades in the U.S. over the counter market, with each ordinary share equivalent to 1 ADR.
05:54 EDTSVUSupervalu downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
December 8, 2014
16:55 EDTCLone Star joins Springleaf as bidder for Citigroup OneMain unit, Bloomberg says
Subscribe for More Information
16:00 EDTCOptions Update; December 8, 2014
Subscribe for More Information
15:40 EDTCLone Star joins Springleaf as bidder for Citigroup OneMain unit, Bloomberg says
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTACTLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
06:35 EDTCValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:21 EDTCDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
December 5, 2014
18:19 EDTCCitigroup's Japanese credit card business sought by three buyers, Nikkei says
Subscribe for More Information
16:49 EDTACTAdvisory Committee recommends approval Of Actavis' ceftazidime-avibactam
Actavis announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections and complicated urinary tract infections caused by Gram-negative pathogens. The committee found the scientific and clinical evidence submitted by Cerexa, a wholly owned subsidiary of Actavis, adequately demonstrated the safety and efficacy of ceftazidime-avibactam in the treatment of the proposed cIAI and cUTI indications. The committee voted not to recommend approval of the combination for hospital-acquired bacterial pneumonia /ventilator-associated bacterial pneumonia and bacteremia.The Advisory Committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for ceftazidime-avibactam during the first quarter of 2015.
11:23 EDTCOption volume leaders
Subscribe for More Information
09:36 EDTCActive equity options trading
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use